Individualized AML Treatment

Abroad (travel likely)Recruiting

Conditions

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

City of Hope Medical Center, Duarte, California, United States
Contact: Study coordinator (Pamela Becker, MD) · pbecker@coh.org · 626-218-2405

Study leads

Pamela Becker, MD
Principal Investigator
City of Hope Medical Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1

Miami, United States · Indianapolis, United States

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE1

Basking Ridge, United States · Middletown, United States

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia · Recurrent Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1

Duarte, United States

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1

Houston, United States